Factor Model (net -1.3)
Factor Model
net -1.3 3.0 / 10FDA approves Sotyktu for psoriatic arthritis indication
Watch: Next major catalyst is August 17 FDA decision on iberdomide for relapsed/refractory multiple myeloma—a first-in-class opportunity worth $13B+ globally that could reshape BMY's growth profile.
Bristol Myers Squibb won FDA approval for Sotyktu (deucravacitinib) to treat active psoriatic arthritis on March 7. Phase 3 data showed 54% of patients achieved ACR20 response by Week 16 versus 34-39% on placebo, with 25% hitting ACR50 response. The drug was already FDA-approved in 2022 for moderate-to-severe plaque psoriasis, so this is label expansion into a second major indication.
Sotyktu label broadening accelerates revenue from an asset already generating cash, reducing approval risk and enabling faster commercial scaling than pipeline molecules. Psoriatic arthritis is a ~$10B global market with limited oral options; this approval positions Sotyktu as a differentiated entrant in an underserved segment and offsets near-term generic Revlimid pressure.
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when BMY changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.